Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
BIIB · Nasdaq · Healthcare
Fundamental quality
57
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $10,982M | $1,556M | $3,382M | — |
| 2022 | $10,173M | $3,047M | $1,144M | — |
| 2023 | $9,836M | $1,161M | $1,270M | — |
| 2024 | $9,676M | $1,632M | $2,722M | — |
| 2025 | $9,891M | $1,293M | $2,051M | — |
Between 2021 and 2025, revenue went from $10,982M to $9,891M (-10%) and net income went from $1,556M to $1,293M (-17%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Biogen Inc. a profitable company?
Yes. Biogen Inc. shows a net margin of 13.8% and an ROE of 7.4%, a sign of a profitable business.
Does Biogen Inc. have a lot of debt?
Not particularly. Its net debt is 1.03 times its EBITDA, a low level.
Is Biogen Inc. growing?
Its revenue has fallen 0.7% annualized in recent years.
Does Biogen Inc. generate cash?
Yes. It converts about 24.4% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Biogen Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →